 Patients age 50 and over with core binding factor acute myeloid leukemia AML e.g., t8;21, inv16, or t16;16 achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator. 